Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:00 PM
Ignite Modification Date:
2025-12-24 @ 7:00 PM
NCT ID:
NCT00515957
Eligibility Criteria:
Inclusion Criteria:
All patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive) in whom the EBV genome or antigens have been demonstrated in tissue biopsies will be eligible for this trial.
Any patient with EBV positive NPC, in relapse or with primary resistant disease
Patients with a life expectancy 6 weeks or greater.
Patients with a Karnofsky score (age at least 16; for Karnofsky scale see full protocol) or Lansky score (less than 16; for Lansky scale see full protocol) of 50 or greater as described below:
Patients with bilirubin \<2x normal, SGOT \<3x normal, and Hgb greater than 8.0.
Patients with a creatinine 2x normal or less for age.
Patients should have been off other investigational therapy for one month prior to entry in this study.
Patient, parent/guardian able to give informed consent.
Exclusion Criteria:
Severe intercurrent infection.
Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom.
Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator¡-s discretion after approval by the CCGT Protocol Review Committee and the FDA reviewer.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00515957
Study Brief:
Protocol Section:
NCT00515957